J Yeungnam Med Sci.  2022 Apr;39(2):124-132. 10.12701/yujm.2021.01347.

The clinical outcomes of second-line chemotherapy in patients with advanced pancreatic cancer: a retrospective study

Affiliations
  • 1Department of Internal Medicine, Kosin University Gospel Hospital, Kosin University College of Medicine, Busan Korea

Abstract

Background
Despite recent advances in first-line chemotherapy for advanced pancreatic cancer, standard treatment after the failure of initial chemotherapy has not been established. Hence, we aimed to retrospectively analyze the clinical characteristics and outcomes of second-line chemotherapy in patients with advanced pancreatic cancer.
Methods
We reviewed the clinical data of patients with advanced pancreatic cancer who underwent palliative chemotherapy at Kosin University Gospel Hospital between January 2013 and October 2020.
Results
Among 366 patients with advanced pancreatic cancer who had received palliative chemotherapy, 104 (28.4%) underwent at least one cycle of second-line chemotherapy. The median age of the patients at the time of initiating second-line treatment was 62 years (interquartile range, 57–62 years), and 58.7% (61 patients) of them were male. The common second-line chemotherapy regimens were 5-fluorouracil (FU) plus leucovorin, irinotecan, and oxaliplatin (33 patients, 31.7%); gemcitabine/nab-paclitaxel (29, 27.9%), gemcitabine±erlotinib (13, 12.5%); and oxaliplatin and 5-FU/leucovorin (12, 11.5%). The median overall survival (OS) and progression-free survival were 6.4 months (95% confidence interval [CI], 4.5–8.6 months) and 4.5 months (95% CI, 2.7–6.3 months), respectively. In a multivariate analysis, poor performance status (PS) (hazard ratio [HR], 2.247; p=0.021), metastatic disease (HR, 2.745; p=0.011), and elevated carcinoembryonic antigen (CEA) levels (HR, 1.939; p=0.030) at the beginning of second-line chemotherapy were associated with poor OS.
Conclusion
The survival outcome of second-line chemotherapy for advanced pancreatic cancer remains poor. However, PS, disease extent (locally advanced or metastatic), and CEA level may help determine patients who could benefit from second-line treatment.

Keyword

Pancreatic adenocarcinoma; Performance status; Prognostic factor; Second-line chemotherapy

Figure

  • Fig. 1. Kaplan-Meier survival after second-line chemotherapy initiation. (A) Progression-free survival (PFS) after second-line chemotherapy initiation in patients with advanced pancreatic cancer. (B) Overall survival (OS) after second-line chemotherapy initiation in patients with advanced pancreatic cancer. CI, confidence interval.


Reference

References

1. Siegel RL, Miller KD, Jemal A. Cancer statistics, 2020. CA Cancer J Clin. 2020; 70:7–30.
2. Conroy T, Desseigne F, Ychou M, Bouché O, Guimbaud R, Bécouarn Y, et al. FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer. N Engl J Med. 2011; 364:1817–25.
3. Von Hoff DD, Ervin T, Arena FP, Chiorean EG, Infante J, Moore M, et al. Increased survival in pancreatic cancer with nab-paclitaxel plus gemcitabine. N Engl J Med. 2013; 369:1691–703.
4. Moore MJ, Goldstein D, Hamm J, Figer A, Hecht JR, Gallinger S, et al. Erlotinib plus gemcitabine compared with gemcitabine alone in patients with advanced pancreatic cancer: a phase III trial of the National Cancer Institute of Canada Clinical Trials Group. J Clin Oncol. 2007; 25:1960–6.
5. Oettle H, Riess H, Stieler JM, Heil G, Schwaner I, Seraphin J, et al. Second-line oxaliplatin, folinic acid, and fluorouracil versus folinic acid and fluorouracil alone for gemcitabine-refractory pancreatic cancer: outcomes from the CONKO-003 trial. J Clin Oncol. 2014; 32:2423–9.
6. Gill S, Ko YJ, Cripps C, Beaudoin A, Dhesy-Thind S, Zulfiqar M, et al. PANCREOX: a randomized phase III study of fluorouracil/leucovorin with or without oxaliplatin for second-line advanced pancreatic cancer in patients who have received gemcitabine-based chemotherapy. J Clin Oncol. 2016; 34:3914–20.
7. Wang-Gillam A, Li CP, Bodoky G, Dean A, Shan YS, Jameson G, et al. Nanoliposomal irinotecan with fluorouracil and folinic acid in metastatic pancreatic cancer after previous gemcitabine-based therapy (NAPOLI-1): a global, randomised, open-label, phase 3 trial. Lancet. 2016; 387:545–57.
8. Ramaswamy A, Parthiban S, Malhotra M, Kothari R, Goel A, Bhargava P, et al. Outcomes with second-line chemotherapy in advanced pancreatic cancers: a retrospective study from a tertiary cancer center in India. Indian J Cancer. 2018; 55:144–7.
9. Tsang ES, Wong HL, Wang Y, Renouf DJ, Cheung WY, Lim HJ, et al. Outcomes and characteristics of patients receiving second-line therapy for advanced pancreatic cancer. Am J Clin Oncol. 2019; 42:196–201.
10. Gränsmark E, Bågenholm Bylin N, Blomstrand H, Fredrikson M, Åvall-Lundqvist E, Elander NO. Real world evidence on second-line palliative chemotherapy in advanced pancreatic cancer. Front Oncol. 2020; 10:1176.
11. Nagrial AM, Chin VT, Sjoquist KM, Pajic M, Horvath LG, Biankin AV, et al. Second-line treatment in inoperable pancreatic adenocarcinoma: a systematic review and synthesis of all clinical trials. Crit Rev Oncol Hematol. 2015; 96:483–97.
12. Rahma OE, Duffy A, Liewehr DJ, Steinberg SM, Greten TF. Second-line treatment in advanced pancreatic cancer: a comprehensive analysis of published clinical trials. Ann Oncol. 2013; 24:1972–9.
13. Pelzer U, Schwaner I, Stieler J, Adler M, Seraphin J, Dörken B, et al. Best supportive care (BSC) versus oxaliplatin, folinic acid and 5-fluorouracil (OFF) plus BSC in patients for second-line advanced pancreatic cancer: a phase III-study from the German CONKO-study group. Eur J Cancer. 2011; 47:1676–81.
14. Kim ST, Choi YJ, Park KH, Oh SC, Seo JH, Shin SW, et al. A prognostic model to identify patients with advanced pancreas adenocarcinoma who could benefit from second-line chemotherapy. Clin Oncol (R Coll Radiol). 2012; 24:105–11.
15. Sinn M, Dälken L, Striefler JK, Bischoff S, Schweitzer N, Pelzer U, et al. Second-Line treatment in pancreatic cancer patients: who profits? Results from the CONKO Study Group. Pancreas. 2016; 45:601–5.
16. Vienot A, Beinse G, Louvet C, de Mestier L, Meurisse A, Fein F, et al. Overall survival prediction and usefulness of second-line chemotherapy in advanced pancreatic adenocarcinoma. J Natl Cancer Inst. 2017; 109:doi: 10.1093/jnci/djx037.
17. Hsu CC, Liu KH, Chang PH, Chen PT, Hung CY, Hsueh SW, et al. Development and validation of a prognostic nomogram to predict survival in patients with advanced pancreatic cancer receiving second-line palliative chemotherapy. J Gastroenterol Hepatol. 2020; 35:1694–703.
18. Lee JE, Lee HS, Chung MJ, Park JY, Park SW, Song SY, et al. Analysis of clinical predictive factors affecting the outcome of second-line chemotherapy for gemcitabine-refractory advanced pancreatic cancer. Gut Liver. 2020; 14:135–43.
19. Colloca G. Performance status as prognostic factor in phase III trials of first-line chemotherapy of unresectable or metastatic pancreatic cancer: a trial-level meta-analysis. Asia Pac J Clin Oncol. 2021; Jun. 23. [Epub]. http://doi.org/10.1111/ajco.13598.
20. Sohal D, Kennedy EB, Khorana A, Copur MS, Crane CH, Garrido-Laguna I, et al. Metastatic pancreatic cancer: ASCO clinical practice guideline update. J Clin Oncol. 2018; 36:2545–56.
21. Ducreux M, Cuhna AS, Caramella C, Hollebecque A, Burtin P, Goéré D, et al. Cancer of the pancreas: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2015; 26(Suppl 5):v56–68.
22. Kim JH, Lee SC, Oh SY, Song SY, Lee N, Nam EM, et al. Attenuated FOLFIRINOX in the salvage treatment of gemcitabine-refractory advanced pancreatic cancer: a phase II study. Cancer Commun (Lond). 2018; 38:32.
23. Portal A, Pernot S, Tougeron D, Arbaud C, Bidault AT, de la Fouchardière C, et al. Nab-paclitaxel plus gemcitabine for metastatic pancreatic adenocarcinoma after FOLFIRINOX failure: an AGEO prospective multicentre cohort. Br J Cancer. 2015; 113:989–95.
24. da Rocha Lino A, Abrahão CM, Brandão RM, Gomes JR, Ferrian AM, Machado MC, et al. Role of gemcitabine as second-line therapy after progression on FOLFIRINOX in advanced pancreatic cancer: a retrospective analysis. J Gastrointest Oncol. 2015; 6:511–5.
25. Viaud J, Brac C, Artru P, Le Pabic E, Leconte B, Bodère A, et al. Gemcitabine as second-line chemotherapy after FOLFIRINOX failure in advanced pancreatic adenocarcinoma: a retrospective study. Dig Liver Dis. 2017; 49:692–6.
26. Sarabi M, Mais L, Oussaid N, Desseigne F, Guibert P, De La Fouchardiere C. Use of gemcitabine as a second-line treatment following chemotherapy with FOLFIRINOX for metastatic pancreatic adenocarcinoma. Oncol Lett. 2017; 13:4917–24.
Full Text Links
  • JYMS
Actions
Cited
CITED
export Copy
Close
Share
  • Twitter
  • Facebook
Similar articles
Copyright © 2024 by Korean Association of Medical Journal Editors. All rights reserved.     E-mail: koreamed@kamje.or.kr